Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 169 participants.

Also called NCT03415503

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 169 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03415503
Other papers using this trial's data
  • Dose-dependent reductions in plasma ceramides after anthocyanin supplementation are associated with improvements in plasma lipids and cholesterol efflux capacity in dyslipidemia: A randomized controlled trial Clinical nutrition (Edinburgh, Scotland), 2021-04 DOI, PubMed 33131908

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03415503. Randomized; double masking; primary purpose prevention. Start 2018-10-01 (actual); primary completion 2019-10-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner
Condition
Dyslipidemias
Intervention (Drug)
Medox® Anthocyanin capsules
Lead sponsor
Sun Yat-sen University (class: other)

Record details

Record id
cardio:ct-nct03415503
Content hash
4b4dc036f2620015964bc50fa8010e41c54f31fb3115e603de21d70baa68b9b8